Last reviewed · How we verify

DualityBio Inc. — Portfolio Competitive Intelligence Brief

DualityBio Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lopinavir and Ritonavir Tablets Lopinavir and Ritonavir Tablets marketed HIV protease inhibitor HIV protease Infectious Disease
DB-1303/BNT323 DB-1303/BNT323 phase 3 Bispecific antibody Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Military Medical University, China · 1 shared drug class
  2. Allakos Inc. · 1 shared drug class
  3. Allergan · 1 shared drug class
  4. Amgen · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Atom Therapeutics Co., Ltd · 1 shared drug class
  7. Baqiyatallah Medical Sciences University · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for DualityBio Inc.:

Cite this brief

Drug Landscape (2026). DualityBio Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dualitybio-inc. Accessed 2026-05-13.

Related